Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant immunochemotherapy for locally advanced cervical cancer
ChiCTR2500100465Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, carboplatin and PD-1 Monoclonal Antibody in Cervical Cancer (CC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective response rate. Started Apr 2025; status: recruiting.
02
Drugs
paclitaxelcarboplatinPD-1 Monoclonal Antibody
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500100465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100465.